Rigel Pharmaceuticals Inc (RIGL)
1.125
-0.02
(-1.32%)
USD |
NASDAQ |
Apr 24, 16:00
1.13
0.00 (0.00%)
Pre-Market: 20:00
Rigel Pharmaceuticals Research and Development Expense (Quarterly): 3.186M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 3.186M |
| September 30, 2023 | 6.475M |
| June 30, 2023 | 4.772M |
| March 31, 2023 | 10.09M |
| December 31, 2022 | 15.36M |
| September 30, 2022 | 14.67M |
| June 30, 2022 | 14.77M |
| March 31, 2022 | 15.47M |
| December 31, 2021 | 13.30M |
| September 30, 2021 | 18.30M |
| June 30, 2021 | 16.81M |
| March 31, 2021 | 16.83M |
| December 31, 2020 | 15.14M |
| September 30, 2020 | 14.60M |
| June 30, 2020 | 14.21M |
| March 31, 2020 | 16.15M |
| December 31, 2019 | 14.25M |
| September 30, 2019 | 14.46M |
| June 30, 2019 | 13.23M |
| March 31, 2019 | 10.95M |
| December 31, 2018 | 13.77M |
| September 30, 2018 | 11.10M |
| June 30, 2018 | 10.80M |
| March 31, 2018 | 11.24M |
| December 31, 2017 | 11.56M |
| Date | Value |
|---|---|
| September 30, 2017 | 10.81M |
| June 30, 2017 | 11.52M |
| March 31, 2017 | 12.38M |
| December 31, 2016 | 11.63M |
| September 30, 2016 | 16.17M |
| June 30, 2016 | 17.47M |
| March 31, 2016 | 18.17M |
| December 31, 2015 | 16.56M |
| September 30, 2015 | 15.50M |
| June 30, 2015 | 15.06M |
| March 31, 2015 | 15.70M |
| December 31, 2014 | 14.61M |
| September 30, 2014 | 16.15M |
| June 30, 2014 | 20.06M |
| March 31, 2014 | 16.87M |
| December 31, 2013 | 18.05M |
| September 30, 2013 | 17.57M |
| June 30, 2013 | 19.39M |
| March 31, 2013 | 20.32M |
| December 31, 2012 | 19.76M |
| September 30, 2012 | 20.19M |
| June 30, 2012 | 20.92M |
| March 31, 2012 | 17.90M |
| December 31, 2011 | 19.82M |
| September 30, 2011 | 17.32M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
3.186M
Minimum
Dec 2023
18.30M
Maximum
Sep 2021
13.27M
Average
14.60M
Median
Sep 2020
Research and Development Expense (Quarterly) Benchmarks
| Nektar Therapeutics | 29.94M |
| Avid Bioservices Inc | -- |
| Stereotaxis Inc | 2.212M |
| Cara Therapeutics Inc | 28.42M |
| Blueprint Medicines Corp | 97.54M |